Safety and tolerability of the selegiline transdermal system 20 mg for treatment of major depression

被引：0

作者：

Robinson, DS ^{[1
]}

Campbell, BJ ^{[1
]}

Amsterdam, JD ^{[1
]}

机构：

[1] Worldwide Drug Dev, Burlington, VT USA

来源：

NEUROPSYCHOPHARMACOLOGY | 2005年 / 30卷

关键词：

D O I：

暂无

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

引用

收藏

页码：S234 / S234

页数：1

相关论文

共 3 条

[1] A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder
Amsterdam, JD
[J]. JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) : 208 - 214
[2] Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients
Bodkin, JA
Amsterdam, JD
[J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) : 1869 - 1875
[3] Daily transdermal administration of selegiline to guinea-pigs preferentially inhibits monoamine oxidase activity in brain when compared with intestinal and hepatic tissues
Mawhinney, M
Cole, D
Azzaro, AJ
[J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 2003, 55 (01) : 27 - 34